 | | Vol. 12.40 – 12 October, 2021 |
| |
|
|
| Scientists generated three lines of transgenic mice with graded erythroid overexpression of erythroferrone and showed that they developed dose-dependent iron overload, impaired hepatic BMP signaling and relative hepcidin deficiency.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors reported an adverse effect of NEAT1, showing that the short isoform, NEAT1_1 suppressed acute myeloid leukemia (AML) development. NEAT1_1 was downregulated in leukemia stem cells and its decreased expression correlated with recurrence in AML patients.
[Advanced Science] |
|
|
|
| Investigators elucidated that the expression of BUB1B increased strikingly in multiple myeloma patients and was closely correlated with poor outcomes. Overexpression of BUB1B facilitated cellular proliferation and induced drug resistance in vitro and in vivo, while genetic targeting BUB1B abrogated this effect.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.
[Science Advances] |
|
|
|
| Scientists reported that FZR1 was downregulated in severe aplastic anemia HSCs compared with healthy control and was associated with decreased quiescence of HSCs.
[Leukemia] |
|
|
|
| The authors found that posttransplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the bone marrow in patient-derived xenograft mice grafted with B cell acute lymphoblastic leukemia cells from multiple patients.
[Cellular & Molecular Immunology] |
|
|
|
| Investigators used next-generation sequencing to explore endogenous miRNAs in chronic myeloid leukemia (CML) patients and found that miR-342-5p was downregulated and had a significant inhibitory effect on cell proliferation in CML.
[Cell Death & Disease] |
|
|
|
| Scientists identified a tumor suppressor role of the acetyltransferase p300 in clinically relevant myelodysplastic syndromes models driven by mutations in the epigenetic regulators TET2, ASXL1, and SRSF2.
[JCI Insight] |
|
|
|
| Researchers used 3D tissue engineered bone marrow to predict the clinical response of individual multiple myeloma patients to different therapeutic regimens.
[Scientific Reports] |
| |
|
|
| Investigators conducted a Phase I trial in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 chimeric antigen receptors (CARs).
[Nature Medicine] |
|
|
|
| The authors investigated a clinically annotated pediatric myelodysplastic syndromes cohort to define the prevalence, genetic landscape, phenotype, therapy outcome and clonal architecture of SAMD9/9L syndromes.
[Nature Medicine] |
|
|
|
| Researchers investigated the frequency and clinical significance of mutations of genes implicated in myeloid malignancies using next-generation sequencing in patients with chronic idiopathic neutropenia with a long follow-up.
[Blood] |
|
|
|
| Scientists adopted CIBERSORTx to estimate the relative fractions of 22 subtypes of immune cells in the bone marrow of 316 myelodysplastic syndrome patients and correlated the results with clinical outcomes.
[Blood Advances] |
|
|
|
|
 | | The authors shed new light on recent advances in the biological characteristics and immunosuppressive functions of myeloid-derived suppressor cells (MDSCs) and propose an overview of current MDSCs-targeting therapies so as to provide new ideas for cancer treatment.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists focus on the immune landscape in patients with myeloproliferative neoplasms – the role of inflammation in disease pathogenesis, susceptibility to infection and emerging strategies for therapeutic immune modulation.
[British Journal of Haematology] |
|
|
|
| Investigators discuss important updates in diagnostic and disease classifications that reflect new understanding of the biology of acute myeloid leukemia, its mutational heterogeneity, some important genetic and environmental risk factors, and new treatment options.
[Bmj Open] |
|
|
|
|
| The Gates Biomanufacturing Facility signed a continued strategic agreement with Nkarta to continue to manufacture NKX101, an immunotherapy currently in a Phase I clinical trial for patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
[Gates Biomanufacturing Facility] |
|
|
|
| Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
[Sutro Biopharma, Inc.] |
|
|
|
|
| November 9 – 10, 2021
Montpellier, France |
|
|
|
|
|
| | University of Manitoba – Winnipeg, Manitoba, Canada |
|
|
|
| | The University of Kansas – Kansas City, Kansas, United States |
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| | Moores Cancer Center, UC San Diego – San Diego, California, United States |
|
|
|
| | Cellectis – Paris, France |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
